The extent of lymph node dissection for gastric cancer: A critical appraisal

Journal of Surgical Oncology

Volumn 102, Issue 6, 2010, Pages 552-562

  De Bree, Eelco ^a   Charalampakis, Vasilis ^a   Melissas, John ^a   Tsiftsis, Dimitris D ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

D1 lymphadenectomy; D2 lymphadenectomy; D3 lymphadenectomy; extended lymphadenectomy; gastric cancer; limited lymphadenectomy; lymph node dissection

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LAPAROSCOPIC SURGERY; LYMPH NODE DISSECTION; LYMPHADENECTOMY; MULTIMODALITY CANCER THERAPY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE BIOPSY; STOMACH CANCER; STOMACH CARCINOMA; SURGICAL MORTALITY; TUMOR LOCALIZATION; UNITED NATIONS;

ADENOCARCINOMA; ASIA; CHEMOTHERAPY, ADJUVANT; GASTRECTOMY; HUMANS; LAPAROSCOPY; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENTINEL LYMPH NODE BIOPSY; STOMACH NEOPLASMS;

EID: 78349246212     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21646     Document Type: Review

References (86)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared to surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
3. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
4. Chua YJ, Cunningham D,: The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: Implications for clinical practice. Ann Surg Oncol 2007; 14: 2687-2690. (Pubitemid 47460625)
5. Sakuramoto S, Sasako M, Yamaguchi T, et al.: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimide. N Engl J Med 2007; 357: 1810-1820.
6. Nakajima T, Kinoshita T, Nashimoto A, et al.: Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa negative locally advanced gastric cancer. Br J Surg 2007; 94: 1468-1476.
7. Kubota T,: The role of S-1 in the treatment of gastric cancer. Br J Cancer 2008; 98: 1301-1304.
8. Yang SH, Zhang YC, Yang KH, et al.: An evidence-based medicine review of lymphadenectomy extent for gastric cancer. Am J Surg 2009; 197: 246-251.
9. Sayegh ME, Sano T, Dexter S, et al.: TNM and Japanese staging systems for gastric cancer: How do they coexist? Gastric Cancer 2004; 7: 140-148.
10. Sobin LH, Wittekind CH, editors. TNM classification of malignant tumors, 6th edition. New York: Wiley-Liss Inc.; 2002.
11. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 2nd English Edition. Gastric Cancer 1998; 1: 10-24.
12. Kajitani T,: Japanese Research Society for the Study of Gastric Cancer. The general rules for gastric cancer study in surgery and pathology. Jpn J Surg 1981; 11: 127-145.
13. Marchet A, Mocellin S, Ambrosi A, et al.: The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy. Results from an Italian multicentric study in 1853 patients. Ann Surg 2007; 245: 543-552.
14. Saito H, Fukumoto Y, Yamada Y, et al.: Prognostic significance of the ratio between metastatic and dissected lymph nodes (n ratio) in patients with advanced gastric cancer. J Surg Oncol 2008; 97: 132-135.
15. Xu DZ, Geng QR, Long ZJ, et al.: Positive lymph node ratio is an independent prognostic factor in gastric cancer after d2 resection regardless of the examined number of lymph nodes. Ann Surg Oncol 2009; 16: 319-326.
16. Maduekwe UN, Lauwers GY, Fernandez-del-Castillo C, et al.: New metastatic lymph node ratio system reduces stage migration in patients undergoing D1 lymphadenectomy for gastric adenocarcinoma. Ann Surg Oncol 2010; 17: 1267-1277.
17. Sun Z, Zhu GL, Lu C, et al.: The impact of N-ratio in minimizing stage migration phenomenon in gastric cancer patients with insufficient number or level of lymph nodes retrieved: Results from a Chinese mono-institutional study in 2159 patients. Ann Oncol 2009; 20: 897-905.
18. Kulig J, Sierzega P, Kolodziejczyk P, et al.: Ratio of metastatic to resected lymph nodes for prediction of survival in patients with inadequately staged gastric cancer. Br J Surg 2009; 96: 910-918.
19. Deng J, Liang H, Wang D, et al.: Enhancement the prediction of postoperative survival in gastric cancer by combining the negative lymph node count with ratio between positive and examined lymph nodes. Ann Surg Oncol 2010; 17: 1043-1051.
20. Japanese Research Society for Gastric Cancer. Japanese classification of gastric cancer, First English Edition. Tokyo: Kancehara & Co., Ltd 1995.
21. Kunisaki C, Shimada H, Yamaoka H, et al.: Significance of para-aortic lymph node dissection in advanced gastric cancer. Hepatogastroenterology 1999; 46: 2635-2642.
22. Bunt Am, Hermans J, Smit VT, et al.: Surgical/pathological stage migration confounds comparison of gastric cancer survival rates between Japan and Western countries. J Clin Oncol 1995; 13: 19-25.
23. Feinstein AR, Sosin DM, Wells CK,: The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Eng J Med 1985; 312: 1604-1608.
24. Bonenkamp JJ, Hermans J, Sasako M, et al.: Extended lymph node dissection for gastric cancer. N Eng J Med 1999; 340: 908-914.
25. Hartgrink HH, van de Velde CJH, Putter H, et al.: Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch Gastric Cancer Group trial. J Clin Oncol 2004; 22: 2069-2077.
26. Cuschieri A, Weeden S, Fielding J, et al.: patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial. Br J Cancer 1999; 79: 1522-1530.
27. Cuschieri A, Fayers P, Fielding J, et al.: Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: Preliminary results of the MRC randomized surgical trial. Lancet 1996; 347: 995-999.
28. Wu C-W, Hsiung CA, Lo S-S, et al.: Nodal dissection for gastric cancer: A randomised controlled trial. Lancet Oncol 2006; 7: 309-315.
29. Wu CW, Hsiung CA, Hsich MC, et al.: Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Br J Surg 2004; 91: 283-287.
30. McCulloch P, Niita ME, Kazi H, et al.: Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer. Br J Surg 2005; 92: 5-13.
31. McCulloch P, Niita ME, Kazi H, et al.: Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev 2004; CD001964.
32. Dent DM, Madden MV, Price SK,: Randomized comparison of R1 and R2 gastrectomy for gastric cancer. Br J Surg 1988; 75: 110-112.
33. Robertson CS, Chung SC, Woods SD, et al.: A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg 1994; 220: 176-182.
34. Csendes A, Burdiles P, Rojas J, et al.: A prospective randomized study comparing D2 total gastrectomy versus total D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery 2002; 131: 401-407.
35. Yu W, Choi GS, Chung HY,: Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006; 93: 559-563.
36. Shin SH, Jung H, Choi SH, et al.: Clinical significance of splenic hilar lymph node metastasis in proximal gastric cancer. Ann Surg Oncol 2009; 16: 1304-1309.
37. Hartgrink HH, van de Velde CJH,: Status of extended lymph node dissection: Locoregional control is the only way to survive gastric cancer. J Surg Oncol 2005; 90: 153-165.
38. Degiuli M, Sasako M, Ponti A, et al.: Morbidity and mortality after D2 gastrectomy for gastric cancer: Results of the Italian Gastric Cancer Study Group prospective multicenter surgical study. J Clin Oncol 1996; 16: 1-4.
39. Degiuli M, Sasako M, Ponti A, et al.: Survival results of a multicentric phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer 2004; 90: 1727-1732.
40. Parikh D, Johnson M, Chagia L, et al.: D2 gastrectomy: Lessons from a prospective audit of the learning curve. Br J Surg 1996; 83: 1595-1599.
41. Lee JH, Ryu KW, Lee JH, et al.: Learning curve for total gastrectomy with D2 lymph node dissection: Cumulative sum analysis for qualified surgery. Ann Surg Oncol 2006; 13: 1175-1181.
42. Degiuli M, Sasako M, Calgaro M, et al.: Morbidity and mortality after D1 and D2 gastrectomy for cancer: Interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomized surgical trial. Eur J Surg Oncol 2004; 30: 303-308.
43. Sano T, Sasako M, Yamamoto S, et al.: Gastric cancer surgery: Morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japanese Clinical Oncology Group study 9501. J Clin Oncol 2004; 22: 2767-2773.
44. Yonemura Y, Wu CC, Fukushima N, et al.: Operative morbidity and mortality after D2 and D4 extended dissection for advanced gastric cancer: A prospective randomized trial conducted by Asian surgeons. Hepatogastroenterology 2006; 53: 389-394.
45. Kullig J, Popiela T, Kolodziejczyk P, et al.: Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: An interim safety analysis of a multicenter, randomized, clinical trial. Am J Surg 2007; 193: 10-15.
46. Sasako M, Sano T, Yamamoto S, et al.: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Eng J Med 2008; 359: 453-462.
47. Yonemura Y, Wu CC, Fukushima N, et al.: Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. Int J Clin Oncol 2008; 13: 132-137.
48. Yoshikawa T, Sasako M, Sano T, et al.: Stage migration caused by D2 dissection with para-aortic lymphadenectomy for gastric cancer from the results of a prospective randomized controlled study. Br J Surg 2006; 93: 1526-1529.
49. Maeta M, Yamashiro H, Saito H, et al.: A prospective pilot study of extended (D3) and superextended para-aortic lymphadenectomy (D4) in patients with T3 or T4 gastric cancer managed by total gastrectomy. Surgery 1999; 125: 325-331.
50. Tokunaga M, Ohyama S, Hiki N, et al.: Can superextended lymph node dissection be justified for gastric cancer with pathologically positive para-aortic lymph nodes? Ann Surg Oncol 2010; epub ahead of print.
51. Tokunaga M, Hiki N, Fukunega T, et al.: Laparoscopic-assisted distal gastrectomy with D2 lymph node dissection following standardization-Preliminary study. J Gastrintest Surg 2009; 13: 1058-1063.
52. Yakoub D, Athanasiou T, Tekkis P, et al.: Laparoscopic assisted distal gastrectomy for early gastric cancer: Is it an alternative to the open approach? Surg Oncol 2009; 18: 322-333.
53. Memon MA, Khan S, Yunus RM, et al.: Meta-analysis of laparoscopic and open distal gastrectomy for gastric carcinoma. Surg Endosc 2008; 22: 1781-1789.
54. Fujiwara M, Kodera Y, Misawa K, et al.: Longterm outcomes of early-stage gastric carcinoma patients treated with laparoscopic-assisted surgery. J Am Coll Surg 2008; 206: 128-143.
55. Kitano S, Shiraishi N, Uyama I, et al.: A multicenter study on oncologic outcome of laparoscopic gastrectomy for early gastric cancer. Ann Surg 2007; 245: 68-72. (Pubitemid 46035437)
56. Lee J-H, Yom C-K, Han H-S,: Comparison of long-term outcomes of laparoscopy-assisted and open distal gastrectomy for early gastric cancer. Surg Endosc 2009; 23: 1759-1763.
57. Kurokawa Y, Sasako M,: Recent advances in chemotherapy and chemoradiotherapy for gastrointestinal tract cancers: Adjuvant chemoradiotherapy for gastric cancer. Int J Clin Oncol 2008; 13: 479-482.
58. Kim S, Lim DH, Lee J, et al.: An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005; 63: 1279-1285.
59. Leong CN, Chung HT, Lee KM, et al.: Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and D2 node dissection for gastric adenocarcinoma. Cancer J 2008; 14: 269-275.
60. Tsang WK, Leung SF, Chiu SK, et al.: Adjuvant chemoradiation for gastric cancer: Experience in the Chinese population. Clin Oncol (R Coll Radiol) 2007; 19: 333-340.
61. Yoshikawa T, Sasako M, Yamamoto S, et al.: Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg 2009; 96: 1015-1022.
62. Wang LB, Shen JG, Xu CY, et al.: Neoadjuvant chemotherapy versus surgery alone for locally advanced gastric cancer: A retrospective comparative analysis. Hepatogastroenterology 2008; 55: 1895-1898.
63. Nakajima T,: Gastric cancer treatment guidelines in Japan. Gastric Cancer 2002; 5: 1-5.
64. Baba H, Maehara Y, Takeuchi H, et al.: Effect of lymph node dissection on the prognosis in patients with node-negative early gastric cancer. Surgery 1994; 117: 165-169.
65. Roukos D, Kappas AM, Encke A,: Effectiveness of extended lymphadenectomy in early gastric cancer. Surgery 1996; 119: 238.
66. Tsujitani S, Oka S, Saito H, et al.: Less invasive surgery for early gastric cancer based on the low probability of lymph node metastasis. Surgery 1999; 125: 148-154.
67. Degiuli M, Calvo F,: Survival of early gastric cancer in a specialized European center. Which lymphadenectomy is necessary? World J Surg 2005; 30: 2193-2203.
68. Hochwald SN, Brennan MF, Klimstra DS, et al.: Is lymphadenectomy necessary for early gastric cancer? Ann Surg Oncol 1999; 6: 664-670.
69. Adachi Y, Shiraishi N, Kitano S,: Modern treatment of early gastric cancer: Review of Japanese experience. Dig Surg 2002; 19: 333-339.
70. Harqunani R, Maclachlan J, Kaniyur S, et al.: Cross-sectional imaging of gastric neoplasia. Clin Radiol 2009; 64: 420-429.
71. Puli SR, Batapati Krishna Reddy J, Bechthold ML, et al.: How good is endoscopic ultrasound for TNM staging of gastric cancers? A meta-analysis and systematic review. World J Gastroenterol 2008; 14: 4011-4019.
72. Ichikura T, Chochi K, Sugasawa H, et al.: Individualized surgery for early gastric cancer guided by sentinel node biopsy. Surgery 2006; 139: 501-507.
73. Yanagita S, Natsugoe S, Uenosono Y, et al.: Detection of micrometastases in sentinel node navigation surgery for gastric cancer. Surg Oncol 2008; 17: 203-210.
74. Kitagawa Y, Fuiji H, Kubo A, et al.: Sentinel lymph node mapping in esophageal and gastric cancer. Cancer Treat Res 2005; 127: 123-139.
75. Tangoku A, Selke J, Nakano K, et al.: Current status of sentinel node navigation surgery in breast and gastrointestinal tract. J Med Invest 2007; 54: 1-18.
76. Bembenek A, Gretschel S, Schlag PM,: Sentinel lymph node biopsy for gastrointestinal cancers. J Surg Oncol 2007; 15: 342-352.
77. Mekicar J, Omejc M,: Preoperative prediction of lymph node status in gastric cancer patients with the help of computer analysis. Dig Surg 2009; 26: 256-261.
78. Briasoulis E, Fatouros M, Roukos DH,: Level I evidence in support of perioperative chemotherapy for operable gastric cancer: Sufficient for wide clinical use? Ann Surg Oncol 2007; 14: 2691-2695.
79. Iwasa S, Yanagawa T, Fan J, et al.: Expression of CXCR4 and its ligand SDF-1 in intestinal-type gastric cancer is associated with lymph node and liver metastasis. Anticancer Res 2009; 29: 4751-4758.
80. Panani AD,: Cytogenetic and molecular aspects of gastric cancer: Clinical implications. Cancer Lett 2008; 266: 99-115.
81. Zhao ZS, Wang YY, Chu YQ, et al.: SPARC is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 2010; 16: 260-268.
82. Wang YY, Ye ZY, Zhao ZS, et al.: High-level expression of S100A4 correlates with lymph node metastasis and poor prognosis in patients with gastric cancer. Ann Surg Oncol 2010; 17: 89-97.
83. Bi J, Lau SH, Lv ZL, et al.: Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Human Pathol 2009; 40: 1790-1797.
84. Okayama H, Kumamoto K, Saitou K, et al.: CD44v6, MMP-7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer. Oncol Rep 2009; 22: 745-755.
85. Roukos DH,: Personal genomics and genome-wide association studies: Novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 2009; 16: 772-773.
86. Roukos DH,: Innovative genomic-based model for personalized treatment of gastric cancer: Integrating current standards and new technologies. Expert Rev Mol Diagn 2008; 8: 29-39.